Literature DB >> 8758931

Activation of Src kinases p53/56lyn and p59hck by p210bcr/abl in myeloid cells.

S Danhauser-Riedl1, M Warmuth, B J Druker, B Emmerich, M Hallek.   

Abstract

Chronic myeloid leukemia is characterized by the Philadelphia (Ph1) translocation t(9;22) that generates a hybrid gene, bcr/abl, translated to a Mr210,000 tyrosine kinase (p210bcr/abl) with transforming activity for hematopoietic cells. Hematopoietic cell transformation by p2l0bcr/abl seems to involve activation of the Ras signaling pathway by at least two different signaling intermediates, growth factor receptor-bound protein 2 and Src homology and collagen protein, but additional signaling proteins are likely to be required as well. In an effort to identify additional phosphoproteins activated by p210bcr/abl, we studied the murine, interleukin 3-dependent, myeloid cell line, 32D, and a bcr/abl-transfected, factor-independent subline, 32Dp210. The analysis of whole-cell lysates of 32D and 32Dp210 cells showed that several proteins with a molecular weight of Mr50,000-60,000 were phosphorylated on tyrosine residues in 32Dp210 cells. Because Src family kinases have an apparent molecular weight of Mr50,000-60,000, we asked whether they could become activated by p2l0bcr/abl. Two Src family kinases, p53/56lyn and p59hck, showed a severalfold higher phosphokinase activity in 32Dp210 cells than in 32D cells. Coimmunoprecipitation experiments with anti-Lyn, anti-Hck, and anti-Abl antibodies demonstrated an intracellular association of p210bcr/abl with p53/56lyn and p59hck. Moreover, the phosphokinase activity of p53/56lyn was higher in bcr/abl-positive myeloid cell lines (K562, BV173, and LAMA84) than in the bcr/abl-negative myeloid cell line JOSK-M. In conclusion, the results show that p210bcr/abl induces the activation of at least two Src family kinases, P53/56lyn and p59hck, in myeloid cells. These findings extend the range of potential targets of p210bcr/abl that might mediate its transforming effects.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8758931

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  47 in total

1.  Expression of a Src family kinase in chronic myelogenous leukemia cells induces resistance to imatinib in a kinase-dependent manner.

Authors:  Teodora Pene-Dumitrescu; Thomas E Smithgall
Journal:  J Biol Chem       Date:  2010-05-07       Impact factor: 5.157

2.  Generation of rac3 null mutant mice: role of Rac3 in Bcr/Abl-caused lymphoblastic leukemia.

Authors:  Young Jin Cho; Bin Zhang; Vesa Kaartinen; Leena Haataja; Ivan de Curtis; John Groffen; Nora Heisterkamp
Journal:  Mol Cell Biol       Date:  2005-07       Impact factor: 4.272

Review 3.  Src family kinases and the MEK/ERK pathway in the regulation of myeloid differentiation and myeloid leukemogenesis.

Authors:  Daniel E Johnson
Journal:  Adv Enzyme Regul       Date:  2007-11-19

Review 4.  Targeted therapy of chronic myeloid leukemia.

Authors:  Con Sullivan; Cong Peng; Yaoyu Chen; Dongguang Li; Shaoguang Li
Journal:  Biochem Pharmacol       Date:  2010-05-12       Impact factor: 5.858

Review 5.  Targeting the leukemic stem cell: the Holy Grail of leukemia therapy.

Authors:  N Misaghian; G Ligresti; L S Steelman; F E Bertrand; J Bäsecke; M Libra; F Nicoletti; F Stivala; M Milella; A Tafuri; M Cervello; A M Martelli; J A McCubrey
Journal:  Leukemia       Date:  2008-09-18       Impact factor: 11.528

6.  Membrane Anchoring of Hck Kinase via the Intrinsically Disordered SH4-U and Length Scale Associated with Subcellular Localization.

Authors:  Matthew P Pond; Rebecca Eells; Bradley W Treece; Frank Heinrich; Mathias Lösche; Benoît Roux
Journal:  J Mol Biol       Date:  2019-12-23       Impact factor: 5.469

7.  The Src family kinase Hck couples BCR/ABL to STAT5 activation in myeloid leukemia cells.

Authors:  Agata Klejman; Steven J Schreiner; Malgorzata Nieborowska-Skorska; Artur Slupianek; Matthew Wilson; Thomas E Smithgall; Tomasz Skorski
Journal:  EMBO J       Date:  2002-11-01       Impact factor: 11.598

8.  Protein tyrosine phosphatase 1B antagonizes signalling by oncoprotein tyrosine kinase p210 bcr-abl in vivo.

Authors:  K R LaMontagne; A J Flint; B R Franza; A M Pandergast; N K Tonks
Journal:  Mol Cell Biol       Date:  1998-05       Impact factor: 4.272

9.  c-Abl and Src-family kinases cross-talk in regulation of myeloid cell migration.

Authors:  Anna Baruzzi; Ilaria Iacobucci; Simona Soverini; Clifford A Lowell; Giovanni Martinelli; Giorgio Berton
Journal:  FEBS Lett       Date:  2010-01-04       Impact factor: 4.124

10.  Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells.

Authors:  Heiko Konig; Mhairi Copland; Su Chu; Richard Jove; Tessa L Holyoake; Ravi Bhatia
Journal:  Cancer Res       Date:  2008-12-01       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.